Report from China Clinical Development Activities in China

被引：0

作者：

Kong, Liang ^{[1
]}

机构：

[1] Room 102,27 Lane 199,Baiyang Rd, Shanghai, Peoples R China

来源：

PHARMAZEUTISCHE INDUSTRIE | 2022年 / 84卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

After around 20 years development since 2003 when China GCP was introduced, China biotech has experienced a significant change, especially in last 10 years when central government started to motivate the innovation and some great reforms has taken place in IND/NDA approval process. More and more innovative products have been launched by domestic companies in China and some of them even started to plan to launch product in US, but it's sure that there will not an easy way to get it done.

引用

页码：773 / 775

页数：3